XML 40 R30.htm IDEA: XBRL DOCUMENT
v3.25.3

Note 7 - Commitments and Contingencies (Details Textual) - USD ($) |  |  |  | 1 Months Ended | 3 Months Ended | 5 Months Ended | 9 Months Ended | 12 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 02, 2025 | Jun. 30, 2024 | Sep. 30, 2022 | Jun. 30, 2024 | Jul. 31, 2018 | Sep. 30, 2025 | Sep. 30, 2024 | Mar. 31, 2017 | Jun. 06, 2024 | Sep. 30, 2025 | Sep. 30, 2024 | Dec. 31, 2024 | Dec. 31, 2009 | Apr. 25, 2025 | Feb. 17, 2025 | Nov. 11, 2024 | Mar. 31, 2023 | Mar. 03, 2021
Costs and Expenses |  |  |  |  |  | $ 3,345,913 | $ 4,323,438 |  |  | $ 11,996,987 | $ 16,838,438 |  |  |  |  |  |  |
License Agreement Terms [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Costs and Expenses |  |  |  |  |  |  |  |  |  | 155,000 | 50,000 |  |  |  |  |  |  |
Contract Payments Incurred and Paid |  |  |  |  |  |  |  |  |  | 525,000 |  |  |  |  |  |  |  |
License Agreement Milestone Payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,150,000
National Institute of Health [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty on Sales, Percentage |  |  |  |  |  |  |  |  |  |  |  |  | 1.00% |  |  |  |  |
Royalty Term (Year) |  |  |  |  |  |  |  |  |  |  |  |  | 21 years |  |  |  |  |
Royalty Payment, Annual Minimum |  |  |  |  |  |  |  |  |  |  |  |  | $ 20,000 |  |  |  |  |
Payment for Contingent Consideration Liability, Operating Activities |  |  |  |  |  |  |  | $ 240,000 |  |  |  |  |  |  |  |  |  |
Contingent Payments Annual Increase |  |  |  |  |  |  |  | $ 20,000 |  |  |  |  |  |  |  |  |  |
Other Commitment |  |  |  |  |  | 400,000 |  |  |  | 400,000 |  | $ 380,000 |  |  |  |  |  |
Research Agreement [Member] | MD Anderson [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Long Term Contract, Estimated Cost |  |  | $ 2,900,000 |  | $ 2,000,000 |  |  |  | $ 2,900,000 |  |  | $ 2,760,000 |  |  |  |  |  |
Long Term Contract, Quarterly Budget Allocated |  |  |  | $ 165,000 |  |  |  |  | $ 240,000 |  |  |  |  |  |  |  |  |
Costs and Expenses |  |  |  |  |  | 165,701 |  |  |  |  |  |  |  |  |  |  |  |
Contract Payments Incurred and Paid |  |  |  |  |  | 2,100,000 |  |  |  |  |  |  |  |  |  |  |  |
License Agreement [Member] | NYU [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract Payments Incurred and Paid |  |  |  |  |  |  |  |  |  | 5,000 |  |  |  |  |  |  |  |
Licensing Fee, Amount |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000 |  |  |  |
Licensing Fee, Amount, Annual, First Two Years |  |  |  |  |  |  |  |  |  |  |  |  |  | 35,000 |  |  |  |
Licensing Fee, Amount, Annual, Third Year |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,000 |  |  |  |
Licensing Fee, Amount, Annual, Fourth and Subsequent Years |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |  |  |  |
Milestone Payment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 400,000 |  |  |  |
License Agreement [Member] | NYU [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Percent, Licensed Technology Covered by Patent |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.00% |  |  |  |
License Agreement [Member] | NYU [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Percent, Licensed Technology Covered by Patent |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.00% |  |  |  |
License Agreement [Member] | University Of Michigan [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Costs and Expenses |  |  |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |
Licensing Fee, Amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 30,000 |  |
Minimum Annual Royalty Fixed Amount, First Two Years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,000 |  |
Minimum Annual Royalty Fixed Amount, Third Year and Thereafter |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 30,000 |  |
License Agreement [Member] | University Of Michigan [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Percent, Licensed Technology Covered by Patent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.00% |  |
Share of Non-Royalty Sublicense Income, Percent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10.00% |  |
License Agreement [Member] | University Of Michigan [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract Payments Incurred and Paid |  |  |  |  |  | 30,000 |  |  |  |  |  |  |  |  |  |  |  |
Royalty Percent, Licensed Technology Covered by Patent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3.00% |  |
Share of Non-Royalty Sublicense Income, Percent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 40.00% |  |
Commercial Sales Milestone, Additional FDA Regulatory Approval |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 350,000 |  |
License Agreement [Member] | University of Pittsburgh [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licensing Fee, Amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000 |  |  |
Annual Maintenance Fee, First Three Years, Amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 65,000 |  |  |
Annual Maintenance Fee, After Year Three, Amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 120,000 |  |  |
License Agreement [Member] | University of Pittsburgh [Member] | Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Costs and Expenses |  |  |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |
Contract Payments Incurred and Paid |  |  |  |  |  | $ 10,000 |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,825,000 |  |  |
Share of Non-Royalty Sublicense Income, Percent |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20.00% |  |  |
Annual Royalty Payment Per Year, Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 250,000 |  |  |
License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member] | Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Percent, Licensed Technology Covered by Patent |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.50% |  |  |
License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member] | Represents Usage of a Glucagon Promoter and Gene Therapy Technologies to Potentially Treat Type 1 and 2 Diabetes [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Percent, Licensed Technology Covered by Patent |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3.00% |  |  |
License Agreement [Member] | UTHealth Houston [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract Payments Incurred and Paid |  |  |  |  |  |  |  |  |  | 10,000 |  |  |  |  |  |  |  |
Licensing Fee, Amount | $ 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual Royalty Payment Per Year, Minimum | 25,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licensing Fee, Amount, Staggered Upfront | 40,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licensing Fee, Amount, Management | 3,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical and Regulatory Expense | $ 360,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Agreement [Member] | UTHealth Houston [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Percent, Licensed Technology Covered by Patent | 0.10% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Agreement [Member] | UTHealth Houston [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Percent, Licensed Technology Covered by Patent | 0.25% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development and Manufacturing of GMP Grade Materials [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Costs and Expenses |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 |  |  |  |  |  |  |
Development Services Agreement, Expected Total Project Cost |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,500,000 |
Contract Payments, Returned to Company |  | $ 1,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition The annual maintenance fee after the third year of an agreement. + References No definition available. + Details
Name: | gnpx_AnnualMaintenanceFeeAfterYearThreeAmount
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of annual maintenance fees for the first three years of an agreement. + References No definition available. + Details
Name: | gnpx_AnnualMaintenanceFeeFirstThreeYearsAmount
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The minimum amount of royalty payment to be received each year. + References No definition available. + Details
Name: | gnpx_AnnualRoyaltyPaymentPerYearMinimum
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the total amount of clinical and regulatory expense. + References No definition available. + Details
Name: | gnpx_ClinicalAndRegulatoryExpense
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The additional amount from the commercial sales milestone payments through the FDA regulatory approval. + References No definition available. + Details
Name: | gnpx_CommercialSalesMilestoneAdditionalFdaRegulatoryApproval
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Annual increase in contingent payment. + References No definition available. + Details
Name: | gnpx_ContingentPaymentsAnnualIncrease
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The value of contract payments incurred and paid. + References No definition available. + Details
Name: | gnpx_ContractPaymentsIncurredAndPaid
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the contract payments that were returned to the company. + References No definition available. + Details
Name: | gnpx_ContractPaymentsReturnedToCompany
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The expected total project cost under development services agreement. + References No definition available. + Details
Name: | gnpx_DevelopmentServicesAgreementExpectedTotalProjectCost
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disclosure of milestone payments made for License Agreements. + References No definition available. + Details
Name: | gnpx_LicenseAgreementMilestonePayment
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of the agreed upon licensing fee. + References No definition available. + Details
Name: | gnpx_LicensingFeeAmount
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the amount of annual licensing fees. + References No definition available. + Details
Name: | gnpx_LicensingFeeAmountAnnualFirstTwoYears
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the amount of annual licensing fees. + References No definition available. + Details
Name: | gnpx_LicensingFeeAmountAnnualFourthAndSubsequentYears
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the amount of annual licensing fee. + References No definition available. + Details
Name: | gnpx_LicensingFeeAmountAnnualThirdYear
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of the management licensing fee. + References No definition available. + Details
Name: | gnpx_LicensingFeeAmountManagement
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of the staggered upfront licensing fee. + References No definition available. + Details
Name: | gnpx_LicensingFeeAmountStaggeredUpfront
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Estimated total cost of of long term contract. + References No definition available. + Details
Name: | gnpx_LongTermContractEstimatedCost
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The quarterly budget allocated to long term contracts. + References No definition available. + Details
Name: | gnpx_LongTermContractQuarterlyBudgetAllocated
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of a payment to be received upon achievement of an agreed upon milestone. + References No definition available. + Details
Name: | gnpx_MilestonePayment
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The minimum fixed amount related to the annual royalties. + References No definition available. + Details
Name: | gnpx_MinimumAnnualRoyaltyFixedAmountFirstTwoYears
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The fixed minimum annual amount related to the royalties. + References No definition available. + Details
Name: | gnpx_MinimumAnnualRoyaltyFixedAmountThirdYearAndThereafter
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of sales of royalty. + References No definition available. + Details
Name: | gnpx_RoyaltyOnSalesPercentage
Namespace Prefix: | gnpx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Minimum of annual royalty payment. + References No definition available. + Details
Name: | gnpx_RoyaltyPaymentAnnualMinimum
Namespace Prefix: | gnpx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percent of net sales of licensed technology covered by patents to be earned as royalty. + References No definition available. + Details
Name: | gnpx_RoyaltyPercentLicensedTechnologyCoveredByPatent
Namespace Prefix: | gnpx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Terms of the royalty agreement, as a percentage of net sales of licensed technologies . + References No definition available. + Details
Name: | gnpx_RoyaltyTerms
Namespace Prefix: | gnpx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The share of non-royalty sublicense income, represented as a percent, to be received as part of an agreement. + References No definition available. + Details
Name: | gnpx_ShareOfNonroyaltySublicenseIncomePercent
Namespace Prefix: | gnpx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total costs of sales and operating expenses for the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_CostsAndExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (ee) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details
Name: | us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gnpx_NationalInstituteOfHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gnpx_ResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gnpx_MdAndersonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gnpx_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gnpx_NyuMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gnpx_UniversityOfMichiganMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gnpx_UniversityOfPittsburghMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=gnpx_RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gnpx_UthealthHoustonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gnpx_DevelopmentAndManufacturingOfGMPGradeMaterialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |